Nothing Special   »   [go: up one dir, main page]

ATE551357T1 - Markerpeptid für die alzheimer-krankheit - Google Patents

Markerpeptid für die alzheimer-krankheit

Info

Publication number
ATE551357T1
ATE551357T1 AT04799415T AT04799415T ATE551357T1 AT E551357 T1 ATE551357 T1 AT E551357T1 AT 04799415 T AT04799415 T AT 04799415T AT 04799415 T AT04799415 T AT 04799415T AT E551357 T1 ATE551357 T1 AT E551357T1
Authority
AT
Austria
Prior art keywords
disease
alzheimer
marker peptide
alcadein
peptide
Prior art date
Application number
AT04799415T
Other languages
English (en)
Inventor
Toshiharu Suzuki
Yoichi Araki
Naomi Miyagi-Toda
Haruyasu Yamaguchi
Masaki Nishimura
Kazuo Yamamoto
Original Assignee
Immuno Biological Lab Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immuno Biological Lab Co Ltd filed Critical Immuno Biological Lab Co Ltd
Application granted granted Critical
Publication of ATE551357T1 publication Critical patent/ATE551357T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT04799415T 2003-11-05 2004-11-01 Markerpeptid für die alzheimer-krankheit ATE551357T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003375363 2003-11-05
PCT/JP2004/016209 WO2005044847A1 (ja) 2003-11-05 2004-11-01 アルツハイマー病のマーカーペプチド

Publications (1)

Publication Number Publication Date
ATE551357T1 true ATE551357T1 (de) 2012-04-15

Family

ID=34567069

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04799415T ATE551357T1 (de) 2003-11-05 2004-11-01 Markerpeptid für die alzheimer-krankheit

Country Status (5)

Country Link
US (2) US7807777B2 (de)
EP (1) EP1690870B1 (de)
JP (1) JP5574559B2 (de)
AT (1) ATE551357T1 (de)
WO (1) WO2005044847A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
PL1976877T5 (pl) 2005-11-30 2017-09-29 Abbvie Inc Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania
ES2527661T3 (es) 2005-11-30 2015-01-28 Abbvie Inc. Método de exploración, proceso para purificar oligómeros Abeta no difundibles, anticuerpos selectivos contra dichos oligómeros Abeta no difundibles y un proceso para fabricar dichos anticuerpos
JP2010505556A (ja) 2006-10-09 2010-02-25 ニューロフルーディクス， インコーポレイテッド 脳脊髄液精製システム
US10850235B2 (en) 2006-10-09 2020-12-01 Minnetronix, Inc. Method for filtering cerebrospinal fluid (CSF) including monitoring CSF flow
US10632237B2 (en) 2006-10-09 2020-04-28 Minnetronix, Inc. Tangential flow filter system for the filtration of materials from biologic fluids
DE102006048201A1 (de) * 2006-10-11 2008-04-17 Ganymed Pharmaceuticals Ag Autoantigene zur verbesserten Diagnose, Prognose und Therapie von entzündlichen neurologischen Erkrankungen
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2486928A1 (de) 2007-02-27 2012-08-15 Abbott GmbH & Co. KG Verfahren zur Behandlung von Amyloidosen
EP2423685A1 (de) * 2007-12-12 2012-02-29 Immuno-Biological Laboratories Co., Ltd. Mittel und Verfahren zur Diagnose bei Auftreten von Morbus Alzheimer
TW201030337A (en) * 2009-02-04 2010-08-16 Tzu Chi Buddhist General Hospital Method and kit for detecting cancers
EP2558494B1 (de) 2010-04-15 2018-05-23 AbbVie Inc. Amyloid-beta-bindende proteine
MX358739B (es) 2010-08-14 2018-09-03 Abbvie Inc Star Proteinas de union a amiloide beta.
JP2014122788A (ja) * 2011-04-04 2014-07-03 Meneki Seibutsu Kenkyusho:Kk アルカデインペプチド切断物による認知症又はアルツハイマー病の診断方法又は予後予測方法
US20160067306A1 (en) * 2013-04-19 2016-03-10 National University Corporation Hokkaido University Treatment agent for cognitive impairment induced by amyloid beta-protein, therapeutic agent for alzheimer's disease, and treatment method and pathological analysis method related to these
WO2015111430A1 (ja) * 2014-01-21 2015-07-30 株式会社 島津製作所 Ａｐｐ切断型ペプチドの測定方法
US11147540B2 (en) 2015-07-01 2021-10-19 Minnetronix, Inc. Introducer sheath and puncture tool for the introduction and placement of a catheter in tissue
ES2856599T3 (es) 2015-12-04 2021-09-27 Minnetronix Inc Sistemas de acondicionamiento de fluido cerebrospinal
CN110426264B (zh) * 2019-08-27 2022-03-22 阜阳师范大学 一种脂肪细胞的染色方法及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001286146A1 (en) * 2000-09-14 2002-03-26 Universitat Zurich Calcium binding proteins
JP4056248B2 (ja) 2001-11-30 2008-03-05 武田薬品工業株式会社 アミロイドβタンパク質産生阻害薬のスクリーニング方法

Also Published As

Publication number Publication date
JP5574559B2 (ja) 2014-08-20
US20070111252A1 (en) 2007-05-17
WO2005044847A1 (ja) 2005-05-19
EP1690870A4 (de) 2007-08-08
EP1690870B1 (de) 2012-03-28
US20110014635A1 (en) 2011-01-20
JPWO2005044847A1 (ja) 2007-11-29
US7807777B2 (en) 2010-10-05
EP1690870A1 (de) 2006-08-16

Similar Documents

Publication Publication Date Title
ATE551357T1 (de) Markerpeptid für die alzheimer-krankheit
MX2007013626A (es) Anticuerpos dirigidos contra el peptido beta amiloide y procedimientos que usan los mismos.
CY1110116T1 (el) Νευροεκφυλιστικοι δεικτες για καταθλιψη
DE69929182D1 (de) Medizinische vorrichtung zur bergung von abgetrennten organteilen mittels schlingen
WO2008021515A3 (en) Methods of determining levels of free amino acids and dipeptides and diagnosing alzheimer's diseases
CY1110252T1 (el) Μεθοδος για την προβλεψη, διαγνωση και διαφορικη διαγνωση της νοσου του αλτζχαιμερ
AT500379B1 (de) Tau-proteine
BR0211623A (pt) Agentes de contraste alvos multiméricos com base em peptìdeo
ATE520981T1 (de) Diagnose und überwachung von krankheiten
WO2005012530A3 (en) Antagonists and agonists of ldcam and methods of use
DK1409544T3 (da) Humane DR4-antistoffer og anvendelser deraf
WO2005012337A3 (en) Antigenic peptides of sars coronavirus and uses thereof
FI20000346A0 (fi) Järjestely biosignaalin mittaamiseksi
ATE375517T1 (de) Diagnosestellung von akuten myokardialen, ischämischen erkrankungen durch kombination von markern
ZA200603178B (en) Quick test for the diagnosis of Alzheimer's disease
DE602004014127D1 (de) Silikon-modifiziertes Protein enthaltende Sonnenschutzzubereitung
DE60219645D1 (de) Antikörper gegen metastin und dessen verwendung zur diagnose von schwangerschaft
ATE495271T1 (de) Zusammensetzungen und verfahren zum nachweis von störungen in verbindung mit histamin
BR0308095A (pt) Teste para anticorpos anti-ingap
ATE445842T1 (de) Nachweis spezifischer nitrierter marker
BR0308978A (pt) fragmentos de peptìdeos sintéticos ativos
WO2003104812A3 (en) DIAGNOSIS ASSAY FOR ALZHEIMER'S DISEASE BASED ON THE DETERMINATION OF THE HA DOLLAR G (B) 42 RATE: HA DOLLAR G (B) 40
DE60334200D1 (de) Verfahren zur messung von neprilysinaktivität
DE602004011478D1 (de) Anzeige der genauigkeit einer quantitativen analyse
ATE511643T1 (de) Fragment des neurosekretorischen proteins vgf als biomarker für morbus alzheimer